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ABSTRACT
Present day cancer incidence and mortality rates indicate the need for effective cancer diagnostic tools
and targeted cancer therapeutic strategies. Recent studies have focused on the biological pathways of cells
and tumor microenvironments to identify putative biomarkers and potential drug targets as diagnostic and
therapeutic tools. Human integrins, adhesion receptors, have become the focal points in these studies,
specifically Integrin Alpha 6 (ITGA6) which has been implicated in major tumor progression roles:
metastasis and angiogenesis. These characteristics make ITGA6 an excellent candidate for potential drug
or diagnostic target, however, the mechanism by which ITGA6 facilitates tumor progression remains
unclear. Cell culture studies have indicated ITGA6 could be cleaved extracellularly to increase metastasis
but, zebrafish with organismal structures and vascular network, present a complete in vivo model to track
metastasis. Our previous studies indicate that truncated ITGA6 overexpression significantly upregulates
tumor metastasis compared to full-length ITGA6 overexpression. Similarly, mutated ITGA6 significantly
decreases tumor metastasis. These results suggest that cleaved ITGA6 increases tumor metastasis,
potentially aiding in extracellular matrix remodeling. In this study, we aim to identify the cellular role of
ITGA6 by transplanting ITGA6 siRNA and DNA transfected PC3 cells into zebrafish tumor xenografts.
We anticipate these experiments will help establish the cell and non-cell autonomous roles of ITGA6 during
tumor development. Further, we expect to use high-resolution imaging techniques to track the migration of
single cancer cells in an in vivo system to understand the dynamics of metastasis.
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CHAPTER 1
INTRODUCTION
1.1 Cancer
Cancer has been classified as a global epidemic, as present-day cancer incidence
and mortality rates continue to rise (WHO, 2017). Cancer is a class of diseases
characterized by the fundamental abnormality of uncontrollable cell division. Cancer cells
are able to ignore the molecular signals which
control normal cell growth and behavior, thus
allowing them to proliferate in an unregulated
fashion. In addition to sustained proliferative
signaling, cancer cells acquire the ability to induce
angiogenesis, resist apoptosis, metastasize and
invade, as well as the ability to avoid immunological
attacks (Hanahan & Weinberg, 2011; Figure 1.1). To

Figure 1.1: Cancer Hallmarks. Cancer cells
acquire new properties, or hallmarks, which
allow for tumor growth and development as
well as metastatic invasion, (Hanahan and
Weinberg. 2011).

date, over 100 different types of cancer have been identified, as abnormal proliferation can
occur in all cell types. Due to the high level of variability amongst cell types, different
types of cancers behave differently at the cellular and molecular levels.
Another source in cancer type variability is the etiology of cancer, which is vast and
includes environmental factors, lifestyle choices, and genetic mutations. Environmental
exposure to carcinogens is a driving force in cancer progression and tumor development
(Parsa, 2012). Several external stimuli have been shown to be associated with cancer
development, and have become classified as risk factors. More specifically, aging, family
history, smoking, alcohol, radiation, chemical exposure, viral infections, hormone therapy,
diet/obesity, and pollution have all been linked to cancer development (Parsa, 2012; Rossi,
et al. 2008; Hassan, et al., 2008; Blackadar, 2016). Genetic causes of cancer have been
well-studied and well described; numerous DNA alterations have been observed in almost
every tumor type (Futreal, P.A., et al., 2004). Genetic mutations are considered the main
mechanism by which cancer presents, as the diverse array of cancer causing factors
ultimately act on cancer genes or proto-oncogenes (Griffiths, et al., 2000). These actions
are typically in the form of cancer gene mutations which activate proto-oncogenes to their
oncogenic state (Griffiths, et al., 2000). The conversion of proto-oncogenes to oncogenes
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is facilitated by a variety of environmentally or spontaneously induced mutations (Chial,
2008; Griffiths, et al., 2000). Tumor suppressor genes are responsible for encoding proteins
which inhibit cancer cell proliferation. Genetic mutations in tumor suppressor genes has
also been identified as major mechanism in tumorigenesis, and several studies have
described this class of tumor-associated genes (Rivlin, et al., 2011; Lodish, et al., 2000,
Eshghifar, et al., 2017; Stewart, et al., 2014).
The term ‘tumor’ refers to an abnormal mass of tissue which may contain solid tissue
or fluid. Tumors are often associated with cancer, however not all tumor growths are
cancerous. Tumors may be classified as benign, non-cancerous, or malignant, cancerous
and typically metastatic. Malignant tumors are monoclonal and develop over a significant
of period time in a process called multistage carcinogenesis (Buffler, P., et al., 2004; Figure
1.2). The inception of tumor development can be initiated by genetic mutations caused by
the previously described factors (i.e. chemicals, radiation, viruses, etc.). Tumorigenesis, or
the process of tumor development, has been categorized into three stages: initiation,

progression, and metastasis (Buffler, P., et al., 2004 & Wang, M. et

Figure 1.2: Carcinogenesis
is a multistep process:
Cancer causing agents
transform normal cells to
‘initiated’ cancer cells via
genetic mutations. Initiated
cells continue to grow and
develop as genetic changes
occur, ultimately resulting
in formation of a metastatic
tumor (Buffler, P., et al.,
al.,2004)
2017).

Initiation refers the point at which normal cells are altered by carcinogens such that their
genetic composition and cellular behaviors are changed. Progression encompasses the
processes involved in tumor development including uncontrollable cell division,
angiogenesis, and invasion. Lastly, metastasis describes the stage in which tumor cells
spread to distant sites in the body. Briefly, these stages are a result of three main causes:
the activation of proto-oncogenes, and the inactivation of both tumor suppressor and
genomic stability genes (Buffler, et al., 2004).

1.1.1 Tumor Developmental Processes

3
As mentioned in the stages of tumorigenesis, tumor cells have the ability to
penetrate and circulate through the vascular system ultimately establishing at another site
(Buffler, et al., 2004 & Nishida, et al., 2006). The extension of the vascular network is a
crucial component in the metastatic spread of tumor cells (Folkman, 2002 & Nishida, et
al., 2006). The process of developing new blood vessels from preexisting blood vessels is
referred to as angiogenesis. The vascular support provided by angiogenesis and
lymphangiogenesis, the formation of lymphatic vessels, allows for metastasis and for an
adequate supply of oxygen, nutrients, and waste removal (Nishida, et al., 2006 & Ziyad, et
al., 2011). Angiogenic growth factors are a class of molecules which act as biological
signals to mediate cross-talk between endothelial cells (EC) and tissue cells (Crivelllato,
2011). A delicate balance of pro- and antiangiogenic factors is altered to favor angiogenesis
in the tumor microenvironment (Merchan, et al., 2015 & Gordon, et al., 2009). Proangigogenic growth factors, like vascular endothelial growth factor-A (VEGF-A),
fibroblast growth factor-2 (FGF-2), or basic fibroblast growth factor (bFGF), and cytokines
stimulate ECs to produce
proteolytic

enzymes

(Campbell, et al., 2010; Figure
1.3).

The

production

proteases,

such

metalloproteinases

of
as

(MMPs),

results in the degradation of
the
(ECM)

extracellular
and

matrix
basement

membrane, proliferation of
Figure 1.3: Tumor Angiogenesis cascade: Tumor cells secrete angiogenic
factors and cytokines to stimulate endothelial cells (ECs; red). EC
stimulation results in the production of proteases which degrade ECM
proteins and allow for proliferation. Tube formation results from the binding
of angiogenic factors to appropriate receptors and occurs to due to a loss of
pericytes (green) (Merchan, J., and Bejarano, T., 2015).

ECs and in cell migration and
invasion (Campbell,

et al.

2010). Angiopeotin-2 (Ang2), a proangiogenic factor,

also works to loosen the ECM and to detach pericytes. A pericyte deficiency paired with a
degraded ECM gives rise to the formation of a new capillary tube (Gordon, et al., 2009).
Blood vessel maturity is mediated by the binding of angiogenic growth factor, Ang-1, to
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its receptor, Tie-2, stimulating pericyte recruitment to the newly formed tubes. Tumor
angiogenesis however, tends to produce fairly immature blood vessels due to the oxygendeprived tumor regions. These conditions require a continuous cycle of angiogenesis in the
tumor microenvironment which further stimulates tumor growth and development
(Gordon, et al., 2009).
Tumor metastasis is the process by which tumor cells invade the circulatory system
and spread locoregionally or systematically to distinct
organs where they establish secondary and tertiary tumor
sites. Despite the fact that metastasis is responsible for
90% of all cancer related deaths, effective therapeutic
strategies against metastatic spread remain unknown
(Seyfried, 2014). Tumor metastasis can be categorized into
four stages: invasion, intravasation, extravasation, and
proliferation/colonization in distinct organs (Figure 1.4).
Cell adhesion plays a major role in metastasis as the loss
of cell-cell adhesion allows tumor cells to dissociate from
the primary tumor site (Martin, et al., 2013). Adhesion
molecules are not completely responsible for metastasis;
however, they mediate important and required steps in the
metastatic process. These molecules facilitate cell-cell
interactions (homotypic adhesion) as well as cell-ECM

Figure 1.4: Stages of Metastasis: Tumor cells
from the primary site invade and intravasate
the blood vessels. Tumor cells then
extravasate and establish at a secondary site
(Gout, S., Tremblay, P., Huot, J., 2007).

interactions (heterotypic adhesion) (Harlozinska, 2005).
The detachment of a tumor cell from its primary site is an example of homotypic adhesion,
and marks the first stage of metastasis, tumor invasion. Tumor cells acquire motile
phenotypes and are able to migrate as single cells or as epithelial sheets. Single migrating
cells may be characterized as amoeboid-like, round-bodied cells with diverse protrusion
types, or as mesenchymal, elongated cells with long protrusions (Glark, et al., 2015).
Collective migration is accomplished by cells that maintain cell-cell adhesion and may
present in a linear lineup or as sheets. Collective groups of cells may also display epithelial
or mesenchymal phenotypes (Glark, et al., 2015). In preparation for metastasis, tumor cells
show changes in their plasticity as demonstrated by the classic epithelial to mesenchymal
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transition (EMT), the collective amoeboid transition (CAT), and the mesenchymal to
amoeboid transition (MAT) (Zijl, et al., 2011).
The epithelial-mesenchymal transition is the process by which polarized epithelial
cells undergo a series of biochemical changes which allow for the acquisition of
mesenchymal phenotypes such as resistance to
apoptosis, cell invasion, and enhanced cell migration
(Kalluri, et al., 2009; Figure 1.5). A complete EMT is
marked by basement membrane degradation and by the
migration of newly formed mesenchymal cells (Kalluri,
et al., 2009). The transition of cancer cells to the
Figure 1.5: Cell migration types:
Cells may undergo EMT maintaining
cell-ECM adhesions (orange dots),
MAT (loss of cell adhesion), or
migrate collectively maintaining cell
adhesions (red rectangles) and cellECM adhesions. ECMs are shown are
black lines (Kawauchi, T., 2012).

mesenchymal type has been termed the “path
generating” mode (Hecht, et al., 2015). Cells that
undergo the mesenchymal to amoeboid transition
(MAT), thus adopting an amoeboid type enter a “path
finding” mode (Hecht, I., et al., 2015). Unlike,

mesenchymal cells, amoeboid cells are unable to degrade the ECM but are still effective in
cell migration due to acquired flexibility traits and loss of cell adhesion (Hecht, et al.,
2015). The amoeboid state seems to be favored in times of metabolic stress suggesting that
it may be more energetically conservative compared to the mesenchymal state (Hecht, et
al., 2015). These changes in plasticity are extremely important for single-cell motility and
have major implications for the metastatic ability of tumor cells. Moreover, these changes
in plasticity allow cancer cells to navigate and migrate through different ECM
environments. The process of cancer cell invasion is critical to the metastatic cascade and
paves for the way for intravasation and extravasation.
The process of establishing a network of microvasculature via angiogenesis allows
cancer cells to access vessels readily. Newly formed capillaries are comprised of disjoint
basement membranes and are leaky, allowing tumor cells to infiltrate easily compared to
mature blood vessels (Weidner, 2002). Intravasation is the entry of tumor cells into the
circulatory system via blood or lymphatic vessels and can occur via active or passive
mechanisms. Evidence for passive intravasation suggest that cells are propelled through
the circulatory system by forces resulting from restricting blood vessel size and by cells
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growing in a confined space (Bockhorn, et al., 2009). Active intravasation may also occur
as the expression of matrix metalloproteinases (MMPs) has been shown to digest ECM
proteins and to degrade vessel basement membranes (Bartolome, et al., 2004 & Bockhorn,
et al., 2009). Once inside the host’s circulatory system, cancer cells must survive the
haemodynamic stressors and the response of the immune system. Extravasation occurs
when tumor cells reach the desired point and initiate biochemical interactions with
endothelial cells (Martin, et al., 2013). This resulting adhesion penetrates the endothelium
allowing the cells to establish and proliferate at the secondary site (Martin, et al., 2013).
1.1.2 Breast and Prostate Cancer
Breast cancer is the leading cause of cancer death in United States women. Breast cancer
refers to abnormal cell division in the breast tissue, typically originating in the milk ducts
or the lobules (Sharma, G.N., et al., 2010; Figure 1.5). The
breast is composed of two tissue types, glandular tissue and
stromal tissue. Stromal tissue refers to the supportiveconnective tissue regions located inside the breasts.
Glandular tissue contains the lobules which are responsible
Figure 1.6: Female Breast
Anatomy. The image depicts the
anterior and cross-section view of
the breast. Breast cancer is most
commonly formed in the ducts
and lobules (CDC, 2017).

for producing milk. There are several types of breast cancer,
though invasive ductal carcinomas (IDC) and invasive
lobular carcinomas (ILC) remain the most common. IDC
accounts for 80% of all breast cancer diagnoses and ILC

accounts for approximately 10% (Sharma, et al., 2010). In addition to the standard causes
of cancer, breast cancer may be caused by hormone replacement therapies (e.g. birth
control pills), significant family history, and a previous history of breast cancer (i.e. a
woman who has developed breast cancer previously). Breast cancer patients often undergo
breast reduction surgery as a viable treatment option. Surgical options include breast
conserving-surgery, Lumpectomy, Quadrantecomy, and Mastectomy. In breast-conserving
surgery, only the tumor and a sample of normal tissue are removed, whereas a mastectomy
removes all breast tissue (Sharma, et al, 2010).
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Prostate cancer is a malignant cancer that forms in the prostate gland and mainly affects
American men. Though several factors including age and ethnicity/race affect prostate
cancer susceptibility, it can be estimated that 1 in 9 men will be diagnosed in his lifetime
(American Cancer Society, 2018).

The prostate is

located between the bladder and penis and is responsible
for producing the alkaline seminal fluid expelled during
ejaculation (Figure 1.7). Androgens are a group of
hormones required for male sexual development and
have been implicated in prostate cancer progression.
Specifically, mutations in androgen receptors have been
shown to decrease ligand specificity (Heinlein, et al.,
2004; Brooke, et al., 2009; Lallous, et al., 2016). The
most

common

type

of

prostate

cancer

is

Figure 1.7: Anatomy of the Male
Reproductive System. The prostate gland
is responsible for producing seminal fluid
and projecting the fluid through the
urethra during ejaculation. Here, the
prostate gland is shown with cancerous
tissue (yellow) (Chundsell Medicals,
2017).

adenocarcinoma, a malignant cancer that originates in the glandular tubes and duct lining.
Other types of prostate cancers include sarcomas, small cell prostate cancer, transitional
cell carcinomas, and neuroendocrine tumors. Similar to breast cancers, prostate cancers
can be highly metastatic, and treatment options include surgery, hormone therapy, or
chemotherapy.
1.1.3 Cancer Diagnostics & Therapeutics
Cancer diagnostics are a critical component of cancer care as they allow physicians
and scientists to not only detect, but monitor and track disease progression. Commonly
used diagnostic methods include biopsy, imaging procedures (e.g., X-rays, PET/CT, MRI,
etc.), laboratory tests (e.g., blood and urine), physical examinations, and genetic tests. Early
detection of cancer significantly increases one’s chances for successful treatment and
survival, resulting in an emphasis on cancer screening and surveillance research.
Biomarkers, or indicators of disease, are commonly used for screening, staging, diagnosing
and monitoring cancer (Schiffman, et al., 2000). Despite these current diagnostic methods,
the need for an early cancer detection test which exhibits a high efficacy and can be applied
across multiple types of cancer, still exist.
Present day cancer incidence and mortality rates are indicative of ineffective cancer
therapeutics. Despite the increase in cancer mortality over the decades, several cancer
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treatment options exist. Specifically, cancer patients are recommended to use a
combination of current cancer treatments: Surgery, radiation therapy, chemotherapy,
immunotherapy, targeted therapy, hormone therapy, stem cell transplants, and precision
medicine. By far, radiation therapy, surgery, and chemotherapy are the most common
cancer treatments. Radiation therapy is the application of ionizing, or high-energy,
radiation to the DNA of cancer cells to inhibit cell proliferation, ultimately resulting in cell
death (Baskar, et al., 2012). Chemotherapy refers to the use of cytotoxic agents which
inhibit microtubule function, protein function, or DNA synthesis causing an inhibition of
cellular growth or cell death (Vanderbilt-Ingram Cancer Center, 2016). Chemotherapeutics
typically target the cell cycle heavily relying on the differences in proliferation speeds that
exist between normal and cancerous cells. Obstacles to chemotherapy include the hypoxic
tumor microenvironments, the heterogeneity of cancer, and drug resistance (Sak, 2012). In
addition, surgical techniques are often used to remove malignant growths, prevent cancer
(i.e. mastectomy), diagnose and grade cancer, as well as repair tissues damaged by other
treatment types. Though each of these treatment options has demonstrated marginal
success, they are each accompanied by host of side effects, and are unable to cure cancer.

1.2 Integrins
Integrins are a superfamily of transmembrane proteins and
cell adhesion receptors that facilitate cell-cell and cell-ECM
communication. Integrins are heterodimeric molecules
consisting two non-covalently bound glycoproteins, the α
and β subunit (Figure 1.8). At least 18 alpha and eight beta
subunits have been identified in humans, each combining to
form 24 distinct integrin heterodimers (Betsy, et al., 2010 &
Takada, et al., 2007). Further, integrins are responsible
for mediating adhesion to the basement membrane, cell
migration through ECM, the formation of ECMs,
bacterial and viral entry during infectious diseases, and
the formation of platelet aggregates (Danen, 2013). The
extracellular region of integrin proteins binds to ECM

Figure 1.8. Integrin Protein Structure. Integrins
are heterodimeric molecules composed of an
alpha and beta subunit. These proteins are
considered transmembrane linkers as they bind to
the matrix (extracellularly) and the cytoskeleton
(intracellularly). The integrin shown is a
fibronectin receptor which displays an alpha
chain that has been cleaved into two portions, and
a beta chin with a cysteine-rich domain (Alberts
B, Johnson A, Lewis J, et al., 2002).
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glycoproteins like laminins, collagens, and fibronectins. Integrins also function as
transmembrane linkers between the ECM and the actin cytoskeleton. In addition, these cell
adhesion receptors are able to modulate signaling cascades which regulate cell motility,
survival, and differentiation (Danen, 2013). The role of integrins in the regulation of cell
motility through ECM interactions has been well studied and is the basis for implications
of integrins in cancer progression.
Several studies have demonstrated the roles of integrins in tumor development,
highlighting their roles in ECM remodeling, cell motility/invasion, tumor cell survival and
modulation of metastatic signaling (Schaffner, et al., 2013; King, 2008; Ganguly, 2013;
Aoudjit, F., et al., 2012; Chen, et al., 2014). Integrins receive environmental cues from
interactions with the ECM and depending on the signal are able to promote cell survival or
cell death. This is mainly regulated by integrin ligation; ligated integrins tend to relay
survival messages while unligated integrins promote apoptosis (Degrosellier, et al., 2015).
In addition, integrin adhesion to the ECM mediates tumor cell invasion by controlling ECM
protein expression and various signaling pathways (Degrosellier, et al., 2015 & Koistinen,
et al., 2013). Integrins are able to induce the expression of ECM proteases, namely MMPs,
and are able to control MMP activity through direct binding (Koistinen, et al., 2013;
Kessenbrock, et al., 2010; Yue, et al., 2012). Specifically, the production of MMPs is the
result of the cytoplasmic binding of integrin subunits to intracellular proteins. The
combination of ligated integrins and an intact cytoskeleton promotes the activation of focal
adhesion kinase (FAK) which is able to bind to integrin subunits β1, β2, and β3 (Koistinen,
et al., 2013). Ligated integrins also enable FAK autophosphorylation triggering the
MAPK/ERK/JNK pathway and MMP production (Koistinen, et al., 2013). The ability of
integrins to modulate cell signaling and MMP expression serves as one example of integrin
medicated cell invasion.
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1.2.1

Integrin Signaling

As previously discussed integrins are essential for adhesion to the ECM and for signal
transduction. These proteins are able to transmit information bidirectionally through two
modes: “inside-out signaling” and “outside-in signaling” (Figure 1.9). Outside-in signaling
refers to the binding of ECM ligands to the extracellular domains of integrins which

Figure 1.9: Integrin Signaling Modes. Inside-out signaling occurs via the activation of talin by an intracellular signal
(signal A). Talin binds to the β subunit of the integrin and facilitates an unclasping event allowing for ECM ligand
binding. The binding of an ECM ligand stimulates outside-in signaling by inducing the formation of focal adhesion
and cytoskeletal reorganization (signal B). Growth Factor Receptors (GFR) can elicit signals (signal C) or participate
in crosstalk with integrins to transmit information (signal D) (Hamidi, H., et al., 2016).

activates FAK. The autophosphorylation of FAK initiates a signaling cascade that
ultimately transmits external signals to the inside of a cell (Menter, et al., 2012). Inside-out
signaling is initiated intracellularly and depends on activator proteins, talin and kindlin,
binding to the cytoplasmic tails of integrin β subunits (Menter, et al., 2012 & Yue, et al.,
2012). When the cell is stimulated it induces a conformational change which exposes the
head region of the talin protein. The head domain of talin is then free to bind to the β
cytoplasmic tail. This binding displaces the α tail and results in an unclasping event
between the non-covalently bound subunits (Qin, et al., 2004). These intracellular events
ultimately lead to the activation of the adhesion receptor and an increase in affinity for
ECM ligands. In Outside-in signaling, the binding of an ECM ligand triggers the
recruitment of adaptor and signaling proteins inside the cell inducing focal adhesion
formation and reorganization of the actin cytoskeleton (Hamidi, et al., 2016). Additionally,
growth factor receptors can generate signals or participate in crosstalk with integrins to
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transmit messages in response changes in the extracellular environment (Hamidi, et al.,
2016).
1.2.2

Integrin Alpha 6 in Cancer Progression Roles

Integrin Alpha 6 (ITGA6) is the alpha subunit of two proteins, integrin α6 β1 and
integrin α6 β4, which serve as laminin receptors. Integrin α6 is required for the normal
embryonic development of vertebrates and invertebrates and plays an important role in
epithelial regeneration and wound healing in adults (DiPersio et al. 1997; Cress et al., 2017;
Zehr & Sittaramane, 2015; Larjava et al., 1993). In the absence of Integrin α6, mice exhibit
vascular development defects, severe blistering of the skin, and die immediately after birth
(Primo et al., 2010; Cress et al., 2001; Lee et al., 2006). Similarly, itga6 deficient zebrafish
embryos present with abnormal physical characteristics, involuntary shaking, a reduced
formation of central arteries in the hindbrain, as well as an increase in blood vessel dilation
(Zehr & Sittaramane, 2015). In addition to these developmental roles, Integrin α6 has been
implicated in several pro-tumorigenic roles including the promotion of angiogenesis,
metastasis and cancer stem cell propagation (Primo et al., 2010; Lee et al., 2006;
Rabinovitz, et al., 1995; King, et al., 2008; Lathia et al., 2010; Cariati, et al., 2007).
As described previously, angiogenesis is a developmental process in which new blood
vessels are formed from preexisting ones. This process is crucial to tumor development as
this network of blood vessels work to supply the tumor with nutrients and serve as
pathways for metastatic movements. Angiogenesis is heavily regulated by the production
of proangiogenic factors such as VEGF-A and FGF-2 and by antiangiogenic factors. It has
been shown that stimulation with these proangiogenic factors significantly upregulates
ITGA6 expression in human EC in vitro (Primo, et al., 2010). The inducement of ITGA6
expression by angiogenic factors suggest that ITGA6 may play an important role in the
beginning stages of tumor angiogenesis (Primo, et al., 2010). In addition, downregulation
of ITGA6 on laminin-containing matrices has been linked to a reduction in migration and
to a defect in the formation of tubular structures (Primo, et al., 2010). Several studies have
presented similar findings implicating upregulated ITGA6 expression tumor angiogenesis
(Cruz and O’Connor, 2008; Lee et. al., 2006; Bouvard, et. al., 2012).
In addition to this proangiogenic role, Integrin Alpha 6 has been implicated in tumor
metastasis, the spread of cancer cells to distant sites. It has been reported that ITGA6
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interacts with Fn14, a receptor in the tumor necrosis super family, to promote the migration
and invasion of lung carcinoma cells (Jandova, et. al., 2015). Fn14 induces ITGA6
expression and strengthens the formation of ITGA6-dependent anastomosing structures
contributing to an increase in angiogenesis, tumor development, and metastases (Jandova,
et. al., 2015). The upregulation of ITGA6 expression has also been shown to induce
metastasis in esophageal squamous cell carcinoma (ESCC) cells (Kwon et al., 2013).
Further, ITGA6 knockdown via siRNA transfection was shown to reduce ESCC cell
proliferation and invasion (Kwon et al., 2013). Similar results have been replicated in
breast cancer and prostate cancer cell lines (Yang, et. al., 2008 & Rabinovitz, et. al., 1995).
Recent investigations of ITGA6 expression in tumor metastasis have revealed the presence
of a novel structural variant referred to as A6p (King, et. al., 2008). This variant is produced
by the truncation, or cleavage, of the ITGA6 protein. The ITGA6/B1 complex is posttranslationally modified by urokinase plasminogen activator receptor (uPAR) to produce
A6p which lacks the ligand binding extracellular domain (Kacsinta, et. al., 2014). The
cleavage of ITGA6 has been linked to an increase in migration, invasion, and metastasis
while the inhibition of ITGA6 cleavage has been shown to reduce or delay metastasis
(Kacsinta, et. al., 2014 & Landowski, et. al., 2014).
The upregulation of ITGA6 has been well-studied and is linked to the aforementioned
cancer progression roles. However, the downregulation of ITGA6 has also been linked to
metastasis and angiogenesis. It has been shown that missense single nucleotide
polymorphisms (SNPs) for the ITGA6 gene are associated with the development of
papillary thyroid carcinomas (PTC) (Kim et al., 2011). In addition, ITGA6 mutations
which result in low levels of ITGA6 expression have been associated with prostate cancer
susceptibility and development. More specifically, the ITGA6 locus rs12621278 was found
to significantly increase the risk of prostate cancer progression by 2.4-fold (Cheng et al.,
2010). A deficiency in endothelial ITGA6 has been linked to an elevation of VEGFmediated angiogenesis further suggesting that the downregulation of ITGA6 plays an
important role in tumor development (Germain, et al., 2009). Based on these studies it
appears that a reduction in ITGA6 expression may be responsible for the cancer
progression roles associated with this protein. When compared with other studies of
ITGA6, it seems that there is a discrepancy in the literature; both the upregulation and
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downregulation of ITGA6 have severe consequences in terms of cancer progression. Based
on these studies and the identified discrepancy, the significance of ITGA6 expression
should be investigated.

1.3 Zebrafish (Danio rerio) Model System
The zebrafish (Danio rerio) is a tropical
freshwater fish native to Indian rivers. These
Southeast Asian fish emerged as a model organism in
the 1960s. They are currently used as models for drug
discovery, toxicology, cancer, development, and
several other areas of study (Mione, et al., 2010; Dai
Figure 1.10: Zebrafish Development.
Zebrafish develop quickly and in a
transparent fashion. Development can be
visualized from fertilization to the larval
stage. Within 24 hours of fertilization, a
swimming larva can be observed
(Browder, L., Iten L., 1998)

et al., 2013; Shi, et al., 2015; Kithcart, 2017).
Evidence supporting the many advantages of the
zebrafish model chronicles its developmental
properties as well as the many investigative tools

which have been developed. Adult females have a high fecundity and are able to produce
up to 400 eggs under optimal breeding conditions. These eggs are fertilized externally and
develop quickly, allowing for the study of early developmental stages (Figure 1.10). As
larvae, these fish are transparent allowing for visualization of development and its
mechanisms. In addition, zebrafish are able to recapitulate human diseases, making them
an excellent model for cancer based studies. They are amenable to genetic manipulations
and several methods can be used to alter their gene expression patterns. The complete
zebrafish genome has been fully sequenced, and zebrafish share 70% of their genes with
humans. Another major attribute of the zebrafish model is the application of transgenic
technology. Zebrafish genetics allow for the expression of gene(s) of interest, or for the
visualization of particular organs and tissues with fluorescent protein (Stoletov, 2008). The
use of zebrafish in long-term studies is beneficial economically as they are small, easy to
house and cheap to maintain compared to similar models.
1.3.1 Humanized Zebrafish Model System
Here, we employ a humanized zebrafish model system which will allow for the in
vivo investigation of human ITGA6. As previously described, zebrafish present a stable
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and genetically amenable model system. To humanize this system for the purpose of
visualizing cell interactions and tumor metastasis we employ several well-developed
genetic tools. By introducing human ITGA6 RNA to recently fertilized zebrafish embryos
(1-2 cell stage), we can ensure the expression of human ITGA6 protein in the zebrafish. In
addition, human cancer cells can be injected into this system, further humanizing the fish
system. These manipulations result in a humanized animal model in which we are able to
study the interactions between human cancer cells and human ITGA6 in vivo. This type of
model will enable us to address the significance of ITGA6 expression by allowing for the
generation of multiple human constructs. Humanized animal models have been well
established and are a critical component to the study of human disease (Walsh et al., 2017;
Morton, et al., 2016; Santoriello et al., 2012; Brehm, et al., 2011).

1.4 Present Study Aims & Significance
As initially discussed, cancer has become a global epidemic due to the rising
accounts of cancer incidence and mortality rates worldwide. Each year 14 million
individuals are diagnosed with cancer and despite current treatments, cancer incidence
is projected to rise 70% over the next 20 years. This evidence highlights the need for
effective diagnostic strategies and for targeted cancer therapeutics. Recent studies
have focused on investigating the biological pathways of cancer cells, exploring
interactions within the tumor microenvironment, and identifying mechanisms of
tumorigenesis. The major implications of these research focal points are to identify
putative biomarkers and potential drug targets which may combat current cancer
incidence and mortality rates. The present study aims to explore the tumor
microenvironment, specifically focusing on integrins, or cell adhesion proteins. The
ultimate aim of the study is to identify the in vivo role of Integrin Alpha 6 in tumor
development. Previous studies have implicated ITGA6 in tumor angiogenesis and
metastasis; however, the mechanistic roles of this protein in tumor development
remain unclear. This is largely due to competing hypotheses which implicate both the
upregulation and downregulation of ITGA6 in pro-tumorigenic roles. In addition, the
cleavage of ITGA6 may be important to this protein’s cancer progression abilities.
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Based on the discrepancies of ITGA6 expression in primary literature, we have
designed a study which will interrogate ITGA6 expression on three levels: host level,
cellular level, and the ECM level (Figure 1.13). Our previous studies focused on the
host level by manipulating ITGA6 expression within the humanized zebrafish system.
More specifically, human ITGA6 RNA constructs were used to increase expression
levels while non-injected and morpholino (MO) groups were used to represent
decreased ITGA6 expression. Zebrafish possess two copies of the integrin alpha 6
gene: itga6a and itga6b. For the purpose of these host level experiments, antisense
nucleotides were used to target the itga6a version of the protein. Preliminary data
from host level experiments reveal that an increase in ITGA6 expression results in an
increase in tumor metastasis compared to ITGA6 null controls. Further, the role of
ITGA6 cleavage was investigated by comparing the free-floating extracellular domain
of ITGA6 to a mutated, non-cleavable version. We found that the extracellular domain
of ITGA6 also increases tumor metastasis when compared to controls. Embryos
injected with the non-cleavable version of ITGA6 or the knockout of itga6a exhibit
tumor metastasis rates comparable to the non-injected controls.
The current study is a continuation of these experiments and focuses on ITGA6
manipulations on the cellular level. On the cellular level, we are aiming to understand
how ITGA6 expression affects cell behavior and tumor metastasis independent of host
ITGA6 manipulation. Based on preliminary host level data, we hypothesize that
decreasing ITGA6 expression will decrease tumor metastasis. The prostate cancer
cell line, PC3, is employed for all cell manipulation experiments. ITGA6 constructs
will be introduced to the cell line via siRNA and DNA transfections. To decrease
expression, PC3 cells are transfected with ITGA6 siRNA. Two versions of siRNA,
s7492 and s7493, are employed each with different ITGA6 targets. siRNA s7492
targets exon 2 and s7493 targets exon 4 in the ITGA6 gene. Labeled and transfected
PC3 cells are injected into zebrafish embryos (48 hpf) and analyzed for in vivo
metastasis. Based on the assertions of previous studies and host level data, we know
that the upregulation of ITGA6 plays an important role in tumor metastasis. We
hypothesize that increasing ITGA6 expression in cancer cells will lead to an
increase in tumor metastasis. To investigate this role on the cancer cell level, PC3

16
cells are transfected with ITGA6 DNA constructs. Transfected cells are introduced to
the zebrafish (48 hpf) via microinjections. Lastly, we hypothesize that the
introduction of truncated ITGA6 will increase tumor metastasis in zebrafish
embryos (48 hpf). Once injected, zebrafish embryos (48hpf) are monitored for
metastasis.

Figure 1.11: Schematic of Experimental Design: ITGA6 expression is manipulated on three levels, host, cell, and
ECM to provide a complete understanding of mechanistic roles. Expression is manipulated used RNA injections
as well as siRNA and DNA transfections.
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CHAPTER 2
CONSTRUCTS
Host Level Constructs

Human Full Length ITGA6 RNA
•
Human ITGA6 protein
overexpressed in zebrafish.
•
Increased ITGA6 in tumor
microenvironment.

Human Truncated ITGA6 RNA
Cleaved version of human ITGA6
•
expressed in zebrafish.
Tumor microenvironment flooded with •
ITGA6 free-floating domain.

•
•

Human Mutated ITGA6 RNA
Non-cleavable version of human ITGA6
expressed in zebrafish.
Absence of cleave product in tumor
microenvironment.

Cell Level Constructs

Human Full Length ITGA6: GFP DNA
•
Human ITGA6 protein
overexpressed in PC3 cells.
•
GFP tag to allow for
visualization of protein

Human ITGA6: siRNA
Human ITGA6 expression
reduced in PC3 cells.
•
Two siRNAs, s7492 and
s7493 are used.
•

•
•

Human NTM ITGA6 DNA
Cleaved version of human ITGA6
expressed in PC3 cells
NTM: amino terminal of ITGA6: freefloating domain equipped with signal
peptides.

Human ITGA6: GAPDH siRNA
•
Human GAPDH expression
reduced in PC3 cells.
•
Serves as positive control

•
•

Human TMC ITGA6 DNA
Cleaved version of human ITGA6
expressed in PC3 cells
TMC: carboxy terminal of ITGA6, also
referred to as A6p.

Human ITGA6: Negative siRNA
•
Negative Silencer siRNA
•
Serves as Negative control

CHAPTER 3
Figure 2.1: ITGA6 Constructs: Schematic of host level constructs, full length ITGA6, Truncated ITGA6 RNA,
and Mutated ITGA6 RNA. Cellular constructs are also shown and include Full-length ITGA6-GFP DNA, NTM
ITGA6 DNA, TMC ITGA6 DNA, ITGA6 siRNA (s7492 and s7493), GAPDH siRNA (positive control), and
Negative Silencer siRNA (negative control). In addition, not injected and non-transfected controls were used but
are not shown above.
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MATERIALS AND METHODS
3.1 Zebrafish Husbandry
Adult Zebrafish were housed in the AQUAneering system located in the Georgia
Southern animal facility. All experiments were performed in accordance with GSU
Institutional Animal Care and Use Committee guidelines. To collect fertilized eggs, adult
breeding tanks containing males and females (1:1) were set up. Crosses were setup at night
to allow fish a suitable acclimation period. Fish water changes occurred early each
morning, as daylight triggers zebrafish spawning. To obtain eggs, the breeding chamber
with the adult fish was removed, and the egg-containing fish water was filtered to separate
embryos from fish waste. Harvested embryos were resuspended in Embryo Medium (E3),
a water based solution containing methylene blue. For all collected embryos, E3 was
changed daily or as needed. For all experiments, zebrafish used were < 7 days post
fertilization (dpf). Experiments described employed Wild-Type and Tg (fli1a: GFP)
embryos.
3.2 Preparation of ITGA6 DNA Constructs
The isolation of three plasmids, FL-GFP, NTM, and TMC, was used to begin the
transformation process and generation of ITGA6 DNA constructs. These plasmids
are all in a mammalian vector and can be identified through Myc-tag
immunostaining. Lyophilized plasmids were dissolved in 20 uL of nuclease free
water and centrifuged. Next, 100 ng of each DNA construct was added to a 1.5 mL
Eppendorf tube containing 50 uL of competent cells at optimal cell density. The
tubes were placed on ice for 30 minutes before being exposed to 42°C for exactly
30 seconds. After the heat shock, the tubes were placed back on ice for two minutes.
950 uL of SO enriched medium was added to each tube. All tubes were then
incubated and at 37°C for one hour in gently shook. A bacterial lawn was created
on LB agar plates using a steel rod. Bacteria were allowed to grow for 12 hours on
ampicillin containing LB broth. A plasmid extraction kit was used to isolate
plasmid DNA. Glycerol stocks of pcDNA for each constructed were created and
stored at -80°C. The pcDNA3.1(+) plasmid was used for experiments. This
mammalian plasmid is resistant to ampicillin and has a CMV promoter. Stock
pcDNA for each construct was used in all cell transfections of ITGA6.
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3.3 Cell Culture
3.3.1 Thawing
Breast cancer cell line, MDA-MB-231, and prostate cancer cell line, PC-3,
(GeneScript®) were used in all experiments. MDA-MB-231 and PC-3 cells are human
epithelial lines isolated from patients with an adenocarcinoma. MDA-MB-231 cells were
isolated from a female patient, while PC-3 cells were isolated from a male patient. Vials
containing 1 X 106 cells were stored in a liquid nitrogen Dewar until thawed for use. In
preparation for thawing, frozen cells were placed in the vapor phase, or in the -80℃
freezer for 24 hours. RMPI 1640 media and frozen cells were warmed in a 37℃-water
bath. The media was warmed for approximately ten minutes, while frozen cells were
warmed until the ice was dissolved. After spraying the biological safety cabinet (BSC)
with 70% isopropyl alcohol (IPA), the media, cells, and T-75 flasks were placed in the
hood. Next, 20 milliliters (mL) of warm media were pipetted into each flask. Quickly,
500 microliters (uL) of cell solution were pipetted into each flask, and the flasks were
mixed by gently pipetting up and down. Flasks containing thawed cells were placed in a
37℃ incubator with 5% CO2.
3.3.2 Harvesting
All reagents used for cell harvesting are warmed in a 37℃-water bath and sprayed
with 70% IPA before being placed in the BSC. To prepare culture media, 50 mL of fetal
bovine serum, five mL of penicillin and streptomycin solution are added to 500 mL RMPI
1640. Culture medium is used to sustain and grow cells between experiments and is
changed 24-48 hours before each passage. Phosphate buffered saline (10 X PBS) was
diluted to 1 X PBS using DNase-free distilled water. Serine protease, trypsin (1X) is used
to dissociate adherent cells from tissue-culture treated surfaces. To harvest the cells, the
old media was removed and replaced with ten mL of 1X PBS. The flask was gently rocked
to wash the PBS across the bottom and sides of the flasks. After removing the PBS, five
mL of trypsin-PBS solution are added to the flask. The flask is then placed in incubator
and the cells are trypsinized for three to five minutes. Following trypsinization, the flask is
gently tapped to release adherent cells. Once the cells are in solution, 8 mL of culture media
are added to the flask in order to terminate trypsinization. Next, the culture solution was
placed in 15 mL falcon tube and centrifuged at 970 revolutions per minute (RPM) for five
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minutes. After centrifugation, the cells are resuspended in fresh media and counted using
a hemocytometer. The desired cell concentrations are calculated and placed in a new flask
or plate depending on the experimental set-up.
3.3.3 Cell Labeling
During harvesting, cells intended for labeling are aliquoted into 1 X 106 cells per
microcentrifuge tube. Each aliquot was centrifuged at 500 relative centrifugal force (RCF)
for two minutes. The supernatant was removed and replaced with one mL of R-1 media, or
serum-free media. After resuspending the cells, five uL of CellTracker Green CMFDA Dye
(Thermo Fisher C2925) were added to the microcentrifuge tube. The tube was then rocked
back and forth before a 15-minute incubation period at 37℃. The cells were again
centrifuged at 500 RCF for two minutes after incubation. At the completion of cell labeling,
the cells were resuspended in 200 uL of fresh culture media in preparation for
microinjection. Labeled cells were incubated for up to four hours after final centrifugation.
3.3.4 Immunostaining of Cells
After harvesting, cells intended for immunohistochemical analysis were plated in 4
well chamber slides (Sigma-Aldrich C6807). Each chamber contained 2 X 104 cells
suspended in 500 uL of RPMI 1640 media. A solution of PBS++ which contained 0.9 mM
Calcium Chloride (CaCl2), 0.52 mM Magnesium Chloride (MgCl2), and 0.16mM
Magnesium Sulfate (MgSO4) was used a washing buffer. Cells were washed once with
serum-free media, followed by two washes with PBS++. Cells were then blocked for 15
minutes with PBS-BSA, a PBS++ solution containing 1% Bovine Serum Albumin (BSA).
Next, cells were washed two times with PBS++, fixed with 4% paraformaldehyde (PFA)
for 20 minutes. Excess fix was removed with three PBS++ washes, and cells were
permeabilized for 10 minutes with 0.2% Trition-X-100. Following three additional washes
with PBS++, cells were again blocked with PBS-BSA for 15 minutes. Cells were incubated
with 100 uL of Integrin Alpha 6 (primary antibody) dilution after two washes with PBS++.
Three PBS++ washes then preceded a final 15-minute blocking period with PBS-BSA.
After being washed twice with PBS++, cells were incubated in a dark environment with
100 uL Alexa Fluor 555 dilution. Finally, cells were washed three times with PBS++ and
prepared for imaging analysis.
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3.3.5 ITGA6 Small Interfering RNA (siRNA) Transfections
PC3 cells were plated in a 24 well tissue culture treated plate; each well containing
5 X 104 cells. The plate was incubated for approximately 48 hours before initializing the
transfection protocol. Lipofectamine RNAiMAX reagent (Thermo Fisher 13778-075) was
diluted by adding 150 uL of Opti-MEM medium to 9 uL of Lipofectamine in a
microcentrifuge tube. Stock solutions of the siRNA constructs were diluted to 10 uM
solutions: GAPDH, Negative Control, siRNA s7492, siRNA s7493, siRNA s7494. The
siRNA constructs were further diluted by adding 50 uL of media to three uL of 10uM
siRNA. Next, the diluted siRNA constructs were mixed with the diluted Lipofectamine
RNAiMAX in a 1:1 solution. The siRNA-RNAiMAX solution was then incubated for five
minutes at room temperature. Cells were transfected by adding 250 uL of the incubated
solution to the appropriate wells. The cells were then incubated at 37℃ for 48 hours.
Control cells were transfected with a solution containing only Lipofectamine RNAiMAX
and Opti-MEM medium.
3.3.6 ITGA6 DNA Transfections
PC3 cells were seeded at 80% confluency in a 24 well tissue culture treated plate
and incubated for two days. For each well, 3.75 uL of Lipofectamine 3000 reagent (Thermo
Fisher L3000008) was diluted with 125 uL of Opti-MEM cell culture medium. Next, each
of the DNA constructs were diluted by adding 5 ug of DNA to 250 uL of Opti-MEM
medium and 10 uL of P300 Reagent. Next, 125 uL of diluted DNA construct were added
to 125 uL of diluted Lipofectamine 3000 reagent. The resulting solution was incubated for
15 minutes at room temperature. Lastly, 250 uL of the 1:1 DNA/Lipofectamine 3000
dilution were added to the appropriate wells. DNA constructs included Full-length GFP,
NTM, and TMC. A 1:1 Lipofectamine 3000/Opti-MEM solution was used on control cells.
Cells were incubated at 37℃ with transfection reagenets for 48-72 hours.
3.4 qPCR
3.4.1 RNA Extraction
RNA extraction was performed on previously transfected PC3 cells. Media
containing transfection reagents was aspirated and transfected cells were washed once with
ice cold 1 X PBS. Ice cold PBS was replaced with 1 mL of TRIzol reagent, and cell scrapers
(location) were used to gently detach adherent cells. TRIzol/cell lysate was transferred into
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a 1.5 mL Eppendorf tube and incubated at room temperature for five minutes. After
incubation, 250 uL of Phenol chloroform were added to each tube. The tubes were shook
vigorously using a vortex for approximately 20 seconds. Following a five-minute
incubation at room temperature, samples were centrifuged at 4℃ for five minutes at 10,000
RPM. The aqueous phase resulting from centrifugation was collected and transferred to a
sterile 1.5 mL Eppendorf tube. Next, 550 uL of isopropanol were added to each tube, and
the tubes were again incubated at room temperature five minutes. Due to the expectation
of a low yield, tubes were centrifuged at maximal speed (13,500 RPM) for 30 minutes.
Centrifuged samples were then placed on ice and washed with 1 mL of 75% ethanol in
nuclease-free water. The tubes were mixed gently and recentrifuged at 9,500 RPM for ten
minutes. Ethanol washes were repeated once to enhance purity of sample RNA. Following
centrifugation, ethanol was poured off and pellets were air-dried. The Nano-drop was used
to determine purity and concentration of extracted RNA. Samples with 260/280 ratios of
less than 2.0 were precipitated to improve RNA purity. To precipitate RNA, 50 uL of
filtered 3M sodium acetate (pH = 5.5; location) were added to each tube. Additionally, 150
uL of ice cold 100% ethanol were added the tubes. Samples were stored at -80℃ overnight
to allow for precipitation. The following day, the samples were centrifuged at maximal
speed for 30 minutes at 4℃. The supernatant was removed, and the pellet was washed
with 500 uL of ice cold 70% ethanol. The tubes were then recentrifuged for 10 minutes,
the ethanol was poured off. Pellets were allowed to air-dry and were resuspended in
nuclease-free water. All RNA samples were stored at -80℃ until needed for further
analysis.
3.4.2 cDNA Synthesis
The Invitrogen cDNA synthesis kit (Life Technologies 11752-050) was used to
generate first-strand cDNA. The standard protocol provided by Life Technologies was used
for all samples. Purity and concentrations of cDNA were determined used the Nano-drop.
All cDNA samples were stored at -20℃ until needed for further use (Life Technologies,
2018). Samples with 260/280 ratios of less than 1.8 were not used for further analysis.
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3.4.3 qPCR
To begin quantitative gene expression analysis, cDNA samples, TaqMan® Gene
Expression Assays 20X (catalog numbers (GAPDH, & ITGA6), TaqMan® Universal
Master Mix II, no UNG (Thermo Fisher, PN 4440047) were thawed on ice. Each sample
was prepared in triplicate on the semi-skirted qPCR plates. Each well contained 1 uL of
20X TaqMan® Gene Expression Assay, 10 uL of master mix, 100 ng of cDNA template,
and RNase—free water. The total volume for each well was 20 uL, and the plate remained
on ice during preparation steps. Two TaqMan® Gene Expression Assays were used,
GAPDH and ITGA6. GAPDH was used a housekeeping gene, while ITGA6 assay was
used to detect expression changes in the gene of interest. Each sample was analyzed with
GAPDH gene assay and with ITGA6 gene assay, each performed in triplicate.
Optimization studies also included sample wells with no gene assay, as well as sample
wells with no cDNA template. The QuantStudio 6 Flex Real-Time PCR system (Thermo
Fisher 4485694) and QuantStudio Real-Time PCR software were used to analyze gene
expression. To begin the experimental set up on QuantStudio software, a fast comparative
CT for 96 well block (0.2 mL) was selected. Next, targets, samples, and endogenous
controls were defined and assigned to the appropriate well locations. It should be noted
that FAM and NFQ-MGB were used as reporter and quencher respectively, while ROX
was used a passive reference. The run method applied consisted of two stages, a hold stage
and PCR stage. The hold stage was one step at 95°C for five minutes. The PCR stage
contained three steps: Step 1 (95°C for 15 seconds), Step 2 (60°C for one minute) and Step
3 (72°C for 30 seconds). The PCR stage was run for 40 cycles, and the run method was
optimized for a 20 uL reaction volume. The comparative CT mean and gene expression
plots were used for data analysis.

3.5 Microinjections
Cultured and labeled Human PC3 cells were injected into 2 dpf dechorionated zebrafish
embryos. Embryos were transferred into a gridded agar plate and treated with 0.04%
Tricaine, an anesthetic. Each embryo was injected with PC3 cells into either the
perivitelline space or brain ventricles using the Nanoject IITM Auto-Nanoliter Injector.
Injection needles were prepared using the Flaming/Brown Micropipette Puller (Sutter
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Instrument, P-97) and loaded with labeled PC3 cells (or MDA-MB-231 cells), followed by
mineral oil, which acts a pressure agent. Embryos were washed three times to remove the
effects of the anesthetic and placed in an incubator for later observation and imaging.

3.6 Imaging Analysis
3.6.1 Immunohistochemistical Analysis of Zebrafish
Zebrafish embryos were fixed in 4% paraformaldehyde solution overnight. The
embryos were washed four times in incubation buffer (IB), each wash lasting 30 minutes.
The embryos were washed once in a solution of IB and 1% horse serum for 30 minutes.
The embryos washed in a solution of IB +1% horse serum + mouse primary antibody in a
1:250 dilutions, overnight. The embryos were then washed for four 30 minute washes in
IB, followed by a wash in IB + 1% horse serum. The embryos washed overnight in a
solution of IB + 1% horse serum + Goat anti mouse (secondary antibody) in a 1:500
dilution. Embryos then received 3, ten minute washes with 1X PBS before being fixed in
4% paraformaldehyde overnight. The following day embryos were washed 3 times in ten
minute intervals with a solution of 1X PBS. Embryos were
incubated in 1 mL of 25% glycerol solution for ten minutes, then incubated with 1 mL of
50% glycerol for 10 minutes and finally placed in 70% glycerol and stored in the 4°C
refrigerator.

3.6.2 Mounting
Zebrafish embryos were fixed in 1.5 mL Eppendorf tubes with 1 mL 4% PFA. Fixed
embryos were stored at 4℃ in 24 well plates or 1.5 mL tubes. Fixed embryos were removed
from the 4°C refrigerator and pipetted onto a slide (one embryo per slide) with minimal
70% glycerol. The embryo was oriented under a microscope in symmetrical position, with
the yolk facing down and the head aligned with the tail. A coverslip was gently placed on
top of the embryo and held in place with Vaseline. The coverslip and embryo were sealed
with the 70 % glycerol solution, and stored in a dark environment until used for imaging.
Live Zebrafish embryos were anesthetized with Tricaine solution before being mounted in
chamber slides. A 3% agarose solution was microwaved briefly and approximately 250 uL
of agarose were pipetted into the chamber. The anesthetized zebrafish embryo was then
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pipetted into the agarose and oriented with a small pin. After the agarose solidified, the
chamber slide was filled with a Tricaine/embryo medium solution. The mounted embryo
can then be imaged over a varying period of time.

3.6.3 Confocal Microscopy
Embryos mounted in chamber slides were placed on the laser confocal for visualization
of injected cells and blood vessels. The laser scanning confocal microscope uses ZEN
software to collect and analyze images or time lapses. Using the ZEN software, preferred
settings were applied to enhance fluorescent visualization of the embryo and cancer cells.
Once settings were selected, mounted embryos underwent Z-stack imaging or time lapse
experiments.

3.6.4 Analysis of Cell Morphology
PC3 cells were harvested, plated in a 4-well chamber slide and transfected as previously
described. Transfected and control cells were labeled with Green Cell Tracker and imaged
at 10X using the laser scanning confocal and ZEN software. Tilescan images were analyzed
using FIJI. Images were made binary and corrected to exclude edges, fill holes, and remove
debris. Binary images were analyzed using the analyze particle functions on FIJI. Cell area,
circularity and aspect ratio were analyzed. Statistics were calculated using Graph Pad Prism
Software.

26
CHAPTER 4
RESULTS & DISCUSSION
4.1 Expression of ITGA6 in Prostate Cancer (PC3) Cells
Integrin Alpha 6 is expressed in several types of human tumors including gastric,
breast, prostate, leukemic, astrocytoma, and ovarian cancers (Lathia, et al., 2010 &
ITGA6-Gene Cards. To confirm the presence of ITGA6 expression in PC3 cells,
immunostaining of non-manipulated, control, cells was performed. PC3 cells were fixed
and stained using an ITGA6 primary antibody (Life Technologies). The immunostaining
revealed that ITGA6 is expressed in the PC3 cell line employed for all other experiments
(Figure 4.1).

Figure 4.1: ITGA6 Expression in PC3 Cells: ITGA6 expression was visualized in fixed PC3 cells by
immunohistochemical analysis. A) Control PC3 cells were not stained and therefore do not exhibit GFP
expression. B) PC3 cells were fixed and stained using an ITGA6 primary antibody followed by an Alexa Fluor
488 secondary antibody (ITGA6 labeled in green).

4.2 siRNA Transfection of PC3 Cells Reduces ITGA6 Expression
We have previously shown that ITGA6 is expressed in PC3 Cells (Figure 4.1). Based
on previous studies and preliminary host level data, we hypothesized that low levels of
ITGA6 expression would decrease tumor metastasis. To effectively reduce ITGA6
expression in PC3 cells, ITGA6 siRNAs were transfected into the cell line. Two siRNAs,
with different ITGA6 targets were employed: s7492 and s7493. To verify successful
transfection of the ITGA6 siRNAs, a comparative CT analysis was performed (Figure 4.2).
We show that ITGA6 siRNAs are able to reduce ITGA6 expression in PC3 cells. GAPDH
siRNA was used as a positive control, while all samples were normalized to a control
group. Control transfection cells were treated with Lipofectamine 3000, but were not
transfected with siRNA.
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Figure 4.2: ITGA6 siRNA Transfection
of PC3 Cells: The figure above
demonstrates that both ITGA6 siRNAs,
s7492 (orange) and s7493 (black) are
able to reduce expression of the ITGA6
gene. The positive control, transfected
with GAPDH siRNA, does not exhibit
reduced ITGA6 expression. All samples
were normalized to a non-transfected
control.

4.3 Analysis of Cell
Morphology in ITGA6 siRNA Transfected PC3 Cells
Changes in cell morphology serve as important markers for metastatic potential. Often
times when cancer cells undergo morphological changes they become more metastatic or
lose their metastatic ability altogether. Due to the changes in the expression of adhesion
receptor, ITGA6, changes in morphological characteristics should be assessed in a
metastatic context. Here, we examine the differences of three morphological characters
between transfected and non-transfected cells. An analysis of cell size in terms of area
(um2) reveals no significant differences between controls and siRNA transfected cells
(Figure 4.3). Circularity is measure of how close an object is to a perfect circle and ranges
from 0 (a straight line) to 1 (perfect circle). Cells transfected with ITGA6 siRNA were
found to be closer to a perfect circle than non-transfected cells. Additionally, cells
transfected with s7492 were found to be significantly more circular than s7493 transfected
cells. Lastly, aspect ratio, a measure used to describe the proportion between width and
height, was analyzed. We find that siRNA transfected cells have a significantly lower
aspect ratio when compared to non-transfected controls (Figure 4.4). These data suggest
that when ITGA6 expression is reduced, cells become more circular and less elliptical in
cell shape. It follows then that siRNA transfected cells would be less metastatic than control
cells. Future experiments will be expanded to include DNA constructs and additional
morphological parameters.
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Figure 4.3: Effects of ITGA6 Knockdown on Cancer Cell Morphology: Three morphological characteristics of PC3
cells transfected with ITGA6 siRNA were analyzed: Area (𝜇𝑚2 ), circularity, and aspect ratio. siRNA transfected cell
shapes were compared to a non-transfected control. There were no significant differences in the cell size between s7492
(n=112), s7493 (n=277) transfected cells and non-transfected controls (n=212). Further there was no significant
differences in cell size between the s7492 and s7493 transfected cells. Analysis of circularity reveals a significant
difference between s7492 transfected cells and control cells, where transfected cells appear to be more circular
(p<0.0001). Similarly, s7493 cells also found to be significantly more circular than control cells (p<0.0001). A
comparison of the circularity between s7492 cells and s7493 cells shows that s7492 cells are significantly more circular
than s7493 cells (p<0.0001). Lastly, aspect ratio was used to describe the elliptical character of transfected and nontransfected cells. There is a significant difference in the aspect ratio between control (n=212) and transfected cells s7492
(n=112) and s7493 (n=277) (p<0.0001). However, no significant differences were found s7492 and s7493 transfected
cells. Unpaired, parametric t-tests using Welch’s (p<0.01) were used to analyze these data.

4.4 Preliminary Analysis of Tumor Metastasis with Transfected PC3 Cells
Upon demonstrating the successful transfection and action of ITGA6 siRNAs, we move
to the introduction of this cellular construct to our in vivo model system to analyze the
effects of ITGA6 knockdown on tumor metastasis. PC3 cells transfected with ITGA6
siRNAs were labeled and injected into the brain ventricle of Tg (Fli1a: gfp) zebrafish
embryos (48 hpf). Zebrafish embryos were observed for tumor metastasis, where
metastasis was defined as the spread of at least ten cancer cells from the primary injection
site. Long-term time-lapse experiments of injected zebrafish embryos were performed to
visualize metastasis in vivo (Analysis of time-lapse data is not shown). In addition, to live
imaging, preliminary population based studies were performed to identify the number of
embryos (%) exhibiting tumor metastasis within the different cellular constructs (Figure
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4.3). Approximately 15% of zebrafish embryos injected with non-transfected controls
exhibit tumor metastasis (Figure 4.3). Embryos injected with s7492 transfected cells did
not exhibit tumor metastasis as defined, while only 5.4% of embryos injected with s7493
ITGA6 siRNA present with tumor metastasis (Figure 4.3). In addition, the effects of
increasing ITGA6 expression in PC3 cells were examined. In the presence of FL-GFP
transfected PC3 cells, 44.4% of embryos exhibit tumor metastasis; double the number of
embryos observed in the control group (Figure 4.3). 10% of embryos injected with the
ITGA6 TMC construct show tumor metastasis (Figure 4.3). The expression of ITGA6 was
verified in control and siRNA transfected cells concurrently with tumor metastasis
observations (Figure 4.3.1). Based on these preliminary data, we can form an initial
conclusion implicating the increased expression of ITGA6 in PC3 cells as an enhancer of
tumor metastasis. These data also show that a reduction of ITGA6 expression in the PC3
cells may contribute to a decrease in tumor metastasis.
There are several notable limitations in the present study:
1) ITGA6 siRNA and DNA Transfections: All cellular constructs were generated
through the transfection of ITGA6 siRNA and ITGA6 DNA. The transfection
protocol was optimized using ITGA6 siRNA constructs: s7492 and s7493.
Knockdown of ITGA6 expression was verified using a comparative analysis (CT)
analysis. Initial results from optimization studies revealed that ITGA6 siRNA
transfections were capable of reducing ITGA6 expression in PC3 cells. Likewise,
ITGA6 DNA was transfected to generate additional cellular constructs: FL-GFP,
NTM, and TMC. Due to the low concentrations obtained during RNA extraction,
comparative analysis (CT) analysis could not be used to verify the expression of
DNA constructs. As such, we cannot assume that injected PC3 cells transfected
with ITGA6 DNA were expressing the appropriate construct. The transfection setup, reagents, and incubation time used for siRNA and DNA transfections were
similar suggesting that overall transfection protocol was successful; however,
ITGA6 gene expression should have been quantified in order to form concrete
conclusions.
2) Sample Size: Due to the small sample sizes employed for population-based studies,
these results can only be interpreted as preliminary. A series of replications is
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required to solidify conclusions and to allow for statistical analysis. Sample sizes
for each cellular construct are as follows: s7492 (n=41), s7493 (n=37), FL-GFP
(n=9), TMC (n=10), Control (n=48).
3) Preliminary basis of studies: The ITGA6-tumor metastasis results discussed were
obtained from only two experiments. Therefore, the conclusions drawn may only
be considered preliminary. In addition, these studies and parallel studies are
currently ongoing, and an analysis of complete data may alter initial conclusions.
Further, a concurrent consideration of both host-level data and cell-level data provides
a better understanding of ITGA6 expression in tumor metastasis. Based on our host-level
studies, we concluded that increasing ITGA6 expression in the tumor microenvironment
results in a significance increase in tumor metastasis. In addition, we found that reducing
ITGA6 expression or itga6 expression results in a decrease in tumor metastasis. Host-level
studies also implicate ITGA6 truncation as an enhancer of tumor metastasis. This finding
is further supported by the decrease in tumor metastasis observed when a mutated, noncleavable version of ITGA6 is introduced. Similarly, cellular studies reveal that decreasing
expression of ITGA6 in PC3 cells results in a decrease in tumor metastasis, while
simultaneously an increase in ITGA6 expression seems to promote metastatic spread
(Figure 4.3).

Taken together these studies suggest that the upregulation of ITGA6

expression acts as an enhancer of tumor metastasis independent of its location; in the tumor
microenvironment or within cancer cells. More specifically, these data reveal that ITGA6
can regulate metastasis both inside and outside of the cell. If this is the case, then ITGA6
expression should be studied in the context of ECM and ECM remodeling. ITGA6 may
work by altering the ECM through interactions with ECM proteins like cadherin, laminin,
or fibronectin. As a laminin receptor, it follows that ITGA6 may be modulating ECM
protein behavior by controlling ligand binding and by mediating signaling cues. In
addition, we have shown that truncation of the ITGA6 extracellular domain seems to play
an essential role in increasing tumor metastasis. Perhaps the truncated portion of ITGA6
serves as signal which induces ECM remodeling to produce a more navigable environment
for cancer cells. Based on our studies, the mechanisms by which ITGA6 induces metastasis
remain unclear, however these studies have contributed to the understanding of ITGA6
expression significance. Current and future studies are required to strengthen these results
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and to expand our understanding of ITGA6 mechanics at the level of, host and cell, and
potentially ECM.
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Figure 4.4: Tumor Metastasis in ITGA6
Cellular Constructs: The figure above
demonstrates the effects of ITGA6 cellular
constructs on tumor metastasis. Approximately
14.58% of zebrafish injected with control cells
(n=48) exhibit tumor metastasis. Embryos
injected with s7492 cells (n=41) and s7393 cells
(n=37) show decreased levels of tumor
metastasis. The Full-length GFP construct
(n=10) appears to increase tumor metastasis,
while the ITGA6 TMC (n=9) construct remains
comparable to the control group.

ITGA6 Construct
Metastatic

Figure 4.4.1: Gene Expression of
ITGA6 siRNA Constructs: ITGA6
expression is reduced in PC3 cells
transfected with ITGA6 siRNA
(s7492, s7493). Samples were
normalized to a non-transfected
control (control 2). GAPDH siRNA
was used a positive control.

4.5: An overview of current and future ITGA6 expression studies
To address the limitations, we have previously identified and to expand our
knowledge on ITGA6 mechanics in tumor development, we will describe on-going and
future investigations:


Use of time-lapses to visualize in vivo ITGA6 mechanics and cell behavior:
The aim of this experiment is to visualize the effects of ITGA6 manipulation
on cancer cell behavior and tumor metastasis. We hypothesize that ITGA6
DNA transfected cells will have many protrusions and will successfully
metastasize out of the brain tissues into other embryonic tissues. Cell
behavior can be observed and analyzed in vivo by employing confocal
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microscopy, cell labeling techniques, and Fiji software. Trackmate can be
used to follow individual cells as they metastasize.


Establish Significance of ITGA6 Expression on the Cellular Level: We are
currently repeating ITGA6 siRNA and ITGA6 DNA transfections and
subsequent injection experiments. The aim of these experiments is to shed
light on the roles of ITGA6 inside the cell. ITGA6 DNA constructs are used
to model upregulation and truncation within PC3 cells. ITGA6 siRNA
constructs are used to demonstrate the effects of decreased ITGA6
expression on metastasis. These experiments are ongoing, and several
replications will be required to expand preliminary analyses. Failure to
verify successful transfection of ITGA6 DNA constructs has presented an
obstacle in these studies. In addition, the ITGA6 NTM construct was
excluded from preliminary studies due to complications during transfection.
We are currently working to repeat both siRNA and DNA transfections in
order to visualize the impact of these constructs on tumor metastasis.
Comparative CT analysis will continue to be used a measure of gene
expression. Population based metastasis studies are also ongoing and these
additional data will be used describe the effects of upregulation,
downregulation and truncation on tumor metastasis.



Effects of ITGA6 on Cell Morphology: Here, we described briefly how a
decrease in ITGA6 affects the morphological characteristics of PC3 cells.
We found that cells transfected with ITGA6 siRNA appear to be comparable
in size to non-transfected controls; however, siRNA transfected cells (s7492
and s7493) are more circular and less elliptical compared to control cells.
Future studies will expand on these analyses of cell morphology, as
morphological characteristics may contribute to metastatic ability. A
comparison of the cell morphologies observed in siRNA transfected and
DNA transfected cells may reveal some clues as to why these cells behave
differently. These in vitro analyses of cell morphology complement the in
vivo studies. Further, a 3D cell culture model system should be used to
explore ECM-ITGA6 interaction in vitro.
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ITGA6 Expression and ECM Remodeling: Based on our preliminary
studies, the interactions between ITGA6 and ECM proteins may explain the
role of ITGA6 in tumor metastasis. ECM remodeling refers to changes in
the tumor microenvironment induced by cellular signals or molecular cues.
In future studies, we hope to probe these interactions by using
immunohistochemistry to visualize ECM protein expression in tissue cross
sections. Using the previously discussed ITGA6 constructs, we can
visualize how differential expression of this protein impacts ECM structure
and composition. These data will also us to determine if ITGA6 works
through ECM signaling to control tumor metastasis.

In conclusion, we have shown that increased levels of ITGA6 expression in PC3 cells
leads to an increase in tumor metastasis. These data align with previous studies which have
implicated upregulation of ITGA6 in cancer progression roles. More specifically, Jandova
et al., showed that the upregulation of ITGA6 induces metastasis and angiogenesis through
signaling mechanisms (Jandova et al., 2015). Similarly, Kwon et al., was able to
demonstrate that increased ITGA6 expression contributes to metastasis while ITGA6
siRNA reduces metastasis. These findings were confirmed by our studies which have
shown that siRNA transfected PC3 cells reduce metastasis compared to controls. Due to
the limitations of our study we were unable to identify the rile of truncation in ITGA6
driven metastasis, however current and future studies have been designed to address these
roles. Our findings of reduced ITGA6 expression resulting in decreased tumor metastasis
conflict with other works which show that mutations for the ITGA6 gene amplify cancer
progression roles and increase susceptibility (Cheng et al., 2010; Germain et al., 2009; Kim
et al., 2011). Based on these results, we should investigate the interactions between the
ECM and ITGA6 to provide a complete understanding of ITGA6 expression levels.
Overall, ITGA6 remains a strong candidate for potential cancer therapeutics targets.
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